Inactive Instrument

Shilpa Medicare Ltd Share Price NSE India S.E.

Equities

INE790G01023

Pharmaceuticals

End-of-day quote NSE India S.E.
- INR - Intraday chart for Shilpa Medicare Ltd

Financials

Sales 2022 11.47B 137M 10.96B Sales 2023 10.52B 126M 10.05B Capitalization 19.91B 239M 19.02B
Net income 2022 607M 7.28M 580M Net income 2023 -325M -3.9M -310M EV / Sales 2022 3.58 x
Net Debt 2022 6.58B 78.86M 6.29B Net Debt 2023 7.79B 93.38M 7.44B EV / Sales 2023 2.63 x
P/E ratio 2022
54.7 x
P/E ratio 2023
-61.3 x
Employees -
Yield 2022
0.28%
Yield 2023
-
Free-Float 39.28%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 63 19/11/87
Director of Finance/CFO - 30/05/21
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Chief Executive Officer 63 19/11/87
Director/Board Member 58 01/09/21
Director/Board Member 63 01/09/21
More insiders
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in research and development, manufacturing and sale of oncology drugs and formulations. Its products consist of oncology and non-oncology active pharmaceutical ingredients (APIs), oncology formulations, biosimilars, ophthalmic, oral dissolving films, biochemical diagnostics, organic intermediates, pilot and production scales and transdermal patches. It supplies oncology APIs and intermediates. Its oncology/non-oncology APIs include Capecitabine, Gemcitabine Hydrochloride, Axitinib, Erlotinib HCL, and Irinotecan HCL Trihydrate for various regulated markets, including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-oncology APIs products include Ambroxol (Mucolytic agent) in Europe and Tranexmic Acid and Ursodeoxycholic acid in India. It is also engaged in manufacturing and sale of Lenvatinib Capsules under the brand name Lenshil.
More about the company